title: Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
abstract: The main clinical, morphological, cytochemical, immunological features and therapy results of eleven patients diagnosed as acute myeloblastic leukemia M0 (AML-M0) are reported here. There were no clinical characteristics, abnormalities on physical examination or initial laboratory parameters that distinguished these eleven patients. Bone marrow aspirates were hypocellular in four patients. The leukemic cells were undifferentiated by light microscopy and myeloperoxidase (MPO) and/or Sudan Black B (SBB) stains were negative in all cases. Myeloid differentiation antigens were present on the leukemic cells of all eleven patients, whereas B and T cell markers were clearly negative except for CD4 and CD7 antigens. Whatever the treatment employed survival was very short. Eight of the eleven patients were treated and two achieved complete remission (CR) but only one of them is alive in continuous CR. Our results like those previously reported, suggest that AML-M0 patients have a very poor prognosis with standard induction therapies and should perhaps be considered for experimental therapeutic approaches.
authors.affiliation: Department of Hematology, La Fe University Hospital, Valencia, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Sempere
authors.forename: I
authors.initials: I
authors.lastname: Jarque
authors.forename: M
authors.initials: M
authors.lastname: Guinot
authors.forename: J
authors.initials: J
authors.lastname: Palau
authors.forename: R
authors.initials: R
authors.lastname: García
authors.forename: G F
authors.initials: GF
authors.lastname: Sanz
authors.forename: F
authors.initials: F
authors.lastname: Gomis
authors.forename: M L
authors.initials: ML
authors.lastname: Pérez-Sirvent
authors.forename: L
authors.initials: L
authors.lastname: Senent
authors.forename: M A
authors.initials: MA
authors.lastname: Sanz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001853:Bone Marrow / Q000473:pathology; D002871:Chromosome Banding; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000276:immunology* / Q000473:pathology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000032:analysis; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D003561:Cytarabine; D004317:Doxorubicin; D009195:Peroxidase; D001215:Asparaginase; D013866:Thioguanine; D003630:Daunorubicin